Inventiva Raises €50M Debt Financing To Fund Its Lead Program In NASH Patients

Inventiva IVA has signed a €50 million bullet credit facility agreement with the European Investment Bank.
The company plans to use the facility for its preclinical and clinical pipeline, including to help fund a portion of its Phase 3 clinical trial of lanifibranor in patients with non-alcoholic steatohepatitis (NASH).
Related: Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor.
The facility is divided into two tranches of €25 million each. The disbursement of Tranche A is subject to the completion of certain conditions precedent specified in the credit facility agreement.
Tranche B is subject to the full drawdown of Tranche A and the achievement of certain conditions precedents.
It is expected that the reimbursement of the interests and capital of this credit facility will happen after the publication of the headline results of part 1 of the Phase 3 trial of lanifibranor in patients with NASH, expected in 2H 2024.
Price Action: IVA shares are up 3.40% at $9.10 during the market session on the last check Monday.